MedTrace Logo

Pharmacokinetic Study of Super-boosted Lopinavir/Ritonavir Given With Rifampin

NCT01700790 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2019-05-16

No results posted yet for this study

Summary

The object of this study is to evaluate the pharmacokinetic interactions, short term safety and efficacy of standard dose lopinavir/ritonavir 200mg/50 (two tablets twice daily) given with ritonavir 100 mg three tablets twice daily given in combination with rifampin in HIV-infected persons with tuberculosis

Conditions

Interventions

DRUG

Lopinavir/ritonavir and ritonavir

Two tablets twice daily of Lopinavir/ritonavir 200 mg/50mg with 3 capsules of ritonavir 100 mg twice daily given with rifampin 600 mg daily

Sponsors & Collaborators

  • Oswaldo Cruz Foundation

    collaborator OTHER

  • University of Miami

    lead OTHER

Principal Investigators

  • Catherine Boulanger, MD. · University of Miami Miller Medical School of Medicine

  • Valeria Calvicanti Rolla, MD · Oswaldo Cruz Foundation

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2018-11-17
Completion
2018-12-31

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01700790 on ClinicalTrials.gov